Related Experiment Video

Updated: Mar 22, 2026

Technique of Minimally Invasive Transverse Aortic Constriction in Mice for Induction of Left Ventricular Hypertrophy
08:34

Technique of Minimally Invasive Transverse Aortic Constriction in Mice for Induction of Left Ventricular Hypertrophy

Published on: September 25, 2017

25.8K

Pharmacological treatment of hypertrophic cardiomyopathy: current practice and novel perspectives

Enrico Ammirati1, Rachele Contri2, Raffaele Coppini3

  • 1De Gasperis Cardio Centre, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.

European Journal of Heart Failure
|April 26, 2016
PubMed

Insights

Hypertrophic cardiomyopathy (HCM) treatment is evolving from generic drugs to targeted therapies. New research promises disease-specific pharmacological treatments for this rare heart condition.

Area of Science:

  • Cardiology
  • Pharmacology
  • Translational Research

Background:

  • Hypertrophic cardiomyopathy (HCM) has historically lacked disease-specific treatments, relying on drugs developed for other conditions.
  • Current management of HCM involves established therapies, requiring expertise for complex cases and decisions on when treatment is not indicated.

Purpose of the Study:

  • To review current time-honored therapies for hypertrophic cardiomyopathy (HCM) in a practical, real-world context.
  • To assess specific challenges in HCM management, including dynamic outflow obstruction, end-stage heart failure, and arrhythmia prevention.
  • To discuss emerging pharmacological approaches and their implications for future HCM research.

Main Methods:

  • Review of existing literature on hypertrophic cardiomyopathy (HCM) therapies.
  • Analysis of practical application, including dosing, titration, and risk-benefit profiles of current agents.
  • Discussion of novel therapeutic strategies currently in clinical research.

Main Results:

  • Established therapies can manage HCM manifestations but require specialized knowledge for challenging situations.
  • Specific HCM-related issues like outflow obstruction, heart failure progression, and arrhythmias necessitate tailored treatment strategies.
  • Significant scientific and economic interest is driving the development of new HCM-specific drugs.

Conclusions:

  • Hypertrophic cardiomyopathy (HCM) is poised for advancements in disease-specific pharmacological treatments.
  • Emerging therapies targeting myocardial metabolism, sodium current, and myosin function show promise.
  • Future research directions include further clinical investigation of these novel approaches for HCM.

Keywords:
AmiodaroneBeta-blockersHypertrophic cardiomyopathyLeft ventricular outflow tract obstructionPharmacological treatmentRanolazineSudden cardiac death

More Related Videos

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level06:02

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level

Published on: November 2, 2020

6.3K
Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

4.4K

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
605
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
643
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
631
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
310
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
733